<rdf:RDF xmlns:rdf="http://www.openarchives.org/OAI/2.0/rdf/" xmlns:ow="http://www.ontoweb.org/ontology/1#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:ds="http://dspace.org/ds/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
   <ow:Publication rdf:about="oai:digibug.ugr.es:10481/98715">
      <dc:title>Growth differentiation factor 15 is not modified afterweight loss induced by liraglutide in South Asians and Europids with type 2 diabetesmellitus</dc:title>
      <dc:creator>A. Hoekx, Carlijn</dc:creator>
      <dc:creator>E. Straat, Maaike</dc:creator>
      <dc:creator>B. Bizino, Maurice</dc:creator>
      <dc:creator>van Eyk, Huub J.</dc:creator>
      <dc:creator>J. Lamb, Hildebrandus</dc:creator>
      <dc:creator>A. Smit, Johannes W.</dc:creator>
      <dc:creator>M. Jazet, Ingrid</dc:creator>
      <dc:creator>C. A. de Jager, Saskia</dc:creator>
      <dc:creator>R. Boon, Mariëtte</dc:creator>
      <dc:creator>Martínez Téllez, Borja Manuel</dc:creator>
      <dc:subject>ethnic differences</dc:subject>
      <dc:subject>metabolic diseases</dc:subject>
      <dc:subject>obesity</dc:subject>
      <dc:description>Glucagon-like peptide-1 receptor (GLP-1R) agonists induceweight loss in patients with&#xd;
type 2 diabetes mellitus (T2DM), but the underlying mechanism is unclear. Recently,&#xd;
the mechanism by which metformin induces weight loss could be explained by an&#xd;
increase in growth differentiation factor 15 (GDF15), which suppresses appetite.&#xd;
Therefore, we aimed to investigate whether the GLP-1R agonist liraglutide modifies&#xd;
plasma GDF15 levels in patients with T2DM. GDF15 levels were measured in plasma&#xd;
samples obtained fromDutch Europids andDutch South AsianswithT2DMbefore and&#xd;
after 26 weeks of treatment with daily liraglutide (n = 44) or placebo (n = 50) added&#xd;
to standard care. At baseline, circulating GDF15 levels did not differ between South&#xd;
Asians and Europids with T2DM. Treatment with liraglutide, compared to placebo,&#xd;
decreased body weight, but did not modify plasmaGDF15levels in all patients, orwhen&#xd;
data were split by ethnicity. Also, the change in plasma GDF15 levels after treatment&#xd;
with liraglutide did not correlate with changes in body weight or HbA1c levels. In&#xd;
addition, the dose of metformin used did not correlate with baseline plasma GDF15 levels. Compared to placebo, liraglutide treatment for 26 weeks does not modify&#xd;
plasma GDF15 levels in Dutch Europid or South Asian patients with T2DM. Thus, the&#xd;
weight loss induced by liraglutide is likely explained by other mechanisms beyond the&#xd;
GDF15 pathway.</dc:description>
      <dc:date>2025-01-08T12:51:21Z</dc:date>
      <dc:date>2025-01-08T12:51:21Z</dc:date>
      <dc:date>2024-07-04</dc:date>
      <dc:type>journal article</dc:type>
      <dc:identifier>A. Hoekz, C. et. al.  Experimental Physiology. 2024;109:1292–1304. [https://doi.org/10.1113/EP091815]</dc:identifier>
      <dc:identifier>https://hdl.handle.net/10481/98715</dc:identifier>
      <dc:identifier>10.1113/EP091815</dc:identifier>
      <dc:language>eng</dc:language>
      <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
      <dc:rights>open access</dc:rights>
      <dc:rights>Atribución 4.0 Internacional</dc:rights>
      <dc:publisher>Wiley Online Library</dc:publisher>
   </ow:Publication>
</rdf:RDF>